SP2509: Potent Lysine-Specific Demethylase 1 Antagonist for Cancer Epigenetics

Executive Summary: SP2509 (SKU B4894) is a selective LSD1 antagonist with an IC50 of 13 nM, showing no inhibition of MAO-A or MAO-B (source: product_spec). It disrupts LSD1-CoREST interaction and increases H3K4 trimethylation, resulting in upregulation of tumor suppressors and apoptosis in acute myeloid leukemia (AML) cells (source: workflow_recommendation). SP2509 significantly prolongs survival in AML xenograft mouse models at 25 mg/kg, administered twice weekly (source: product_spec). The compound is insoluble in water and ethanol but dissolves readily in DMSO at ≥19.45 mg/mL (source: product_spec). APExBIO provides SP2509 for research use, supporting reproducible workflows in cancer epigenetics (source: workflow_recommendation).

Biological Rationale

Lysine-specific demethylase 1 (LSD1, also known as KDM1A) plays a crucial role in the epigenetic regulation of gene expression. LSD1 demethylates mono- and di-methylated lysine 4 on histone H3 (H3K4me1/2), modifications associated with transcriptional repression. Overactivity of LSD1 is implicated in the maintenance and progression of several cancers, including acute myeloid leukemia (AML) and hepatocellular carcinoma, where it is correlated with poor prognosis (source: DOI). Targeting LSD1 offers a precise approach to restoring the expression of tumor suppressor genes and modulating cancer cell fate. In AML, LSD1 maintains the undifferentiated, proliferative state of leukemic cells, making its inhibition a compelling strategy for promoting differentiation and apoptosis (source: workflow_recommendation).

Mechanism of Action of SP2509

SP2509 acts as a reversible, non-covalent antagonist of LSD1, with a measured IC50 of 13 nM for LSD1 enzymatic inhibition (source: product_spec). Unlike tranylcypromine-based inhibitors, SP2509 demonstrates no inhibitory activity against monoamine oxidases MAO-A and MAO-B, minimizing off-target effects (source: product_spec). By binding to LSD1, SP2509 disrupts its interaction with the CoREST corepressor complex, impeding the demethylation of H3K4 at gene promoters. This leads to the accumulation of H3K4Me3 marks and facilitates the transcriptional activation of tumor suppressor genes such as p53, p21, and C/EBPα (source: workflow_recommendation). The resultant epigenetic reprogramming induces apoptosis and promotes differentiation in both cultured and primary AML cells (source: workflow_recommendation).

Evidence & Benchmarks

• SP2509 exhibits potent inhibition of LSD1 enzymatic activity with an IC50 of 13 nM under standard in vitro assay conditions (source: product_spec).
• SP2509 does not inhibit MAO-A or MAO-B at concentrations up to 20 µM, ensuring selectivity (source: product_spec).
• In AML cell culture, SP2509 increases H3K4Me3 levels and activates expression of p21, p53, and C/EBPα within 24–48 hours post-treatment (source: workflow_recommendation).
• SP2509 induces apoptosis and promotes differentiation in both established AML cell lines and primary AML blasts (source: workflow_recommendation).
• In vivo, SP2509 at 25 mg/kg intraperitoneally twice weekly significantly extends survival in NOD/SCID mice bearing AML xenografts compared to vehicle (source: product_spec).
• Combination treatment with panobinostat enhances SP2509’s anti-leukemic efficacy in preclinical models (source: product_spec).
• SP2509 is insoluble in water and ethanol but dissolves in DMSO at concentrations ≥19.45 mg/mL at 25°C (source: product_spec).

This article further extends the mechanistic detail provided in SP2509: Selective LSD1 Antagonist for Acute Myeloid Leukemia by benchmarking in vivo efficacy and protocol parameters. For a workflow-focused perspective, see SP2509: Lysine-Specific Demethylase 1 Antagonist for AML Research, which emphasizes troubleshooting and protocol optimization. The translational impact discussed here builds on the scenario-based guidance in Enhancing AML Research with SP2509: A Data-Driven Guide.

Applications, Limits & Misconceptions

SP2509 is principally deployed in preclinical studies of AML and related cancer epigenetics workflows. Its high selectivity for LSD1 makes it a preferred reagent for dissecting the role of histone demethylation in gene regulation and cell fate decisions. The compound has shown utility in both in vitro and in vivo models, including patient-derived AML samples and xenograft mice (source: product_spec). SP2509 is not approved for clinical or diagnostic use in humans.

Common Pitfalls or Misconceptions

• SP2509 is not a covalent LSD1 inhibitor and does not irreversibly inactivate the enzyme (source: product_spec).
• It does not inhibit monoamine oxidases MAO-A or MAO-B, so it should not be used for studies targeting these enzymes.
• SP2509 is insoluble in water and ethanol; improper dissolution can lead to inconsistent dosing or failed experiments (source: product_spec).
• Long-term storage of SP2509 solutions at room temperature or above -20°C leads to compound degradation and reduced activity (source: product_spec).
• It is not suitable for clinical therapy or diagnostic purposes and is intended strictly for research use (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• in vitro LSD1 inhibition assay | IC50 = 13 nM | optimal for AML and cancer epigenetics models | Demonstrates high potency and selectivity | product_spec
• Cell culture treatment | 0.1–1.0 μM | effective in AML cell lines and primary blasts | Induces H3K4Me3 and apoptosis within 48h | workflow_recommendation
• In vivo efficacy | 25 mg/kg IP, twice weekly | NOD/SCID AML xenograft mice | Prolonged survival and reduced tumor burden | product_spec
• Solubility | ≥19.45 mg/mL in DMSO at 25°C | required for stock preparation | Enables accurate dosing, avoid water/ethanol | product_spec
• Storage | solid at -20°C | all applications | Preserves compound stability | product_spec
• Workflow suggestion | warm and sonicate solution before use | lab protocol | Improves dissolution and reproducibility | workflow_recommendation

Conclusion & Outlook

SP2509, as supplied by APExBIO, is a validated, potent LSD1 antagonist that enables precise dissection of epigenetic regulation in AML and related cancer models. Its high selectivity, favorable solubility in DMSO, and proven in vivo efficacy position it as a reliable agent for mechanistic and translational studies in cancer epigenetics. Ongoing research continues to refine its deployment in combination regimens—such as with panobinostat—to maximize therapeutic benefit in preclinical settings (source: product_spec). The evidence base for SP2509 supports its role as a key tool in the study and modulation of histone demethylation pathways in cancer biology.